Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study

{ 'institution': [{'name': 'medRxiv'}], 'indexed': { 'date-parts': [[2022, 12, 22]], 'date-time': '2022-12-22T05:31:07Z', 'timestamp': 1671687067555}, 'posted': {'date-parts': [[2021, 3, 12]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 20, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 3, 22]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>With ' 'over 87,273,380 cases being reported and 1,899,440 deaths worldwide as of 9th January 2021, ' 'Coronavirus disease 2019 (COVID-19) has become the worst-hit pandemic till date. Every day ' 'clinicians are bombarded with many new treatment options that claim to be better than the ' 'others.</jats:p></jats:sec><jats:sec><jats:title>Materials and ' 'methods</jats:title><jats:p>After screening the electronic database of COVID-19 patients ' 'retrospectively, 56 patients with mild COVID-19 infection matched the inclusion criteria and ' 'were divided into the four following groups - group having used Hydroxychloroquine (HCQ), ' 'group using doxycycline (DOX) + Ivermectin (IVR) combination, group receiving only ' 'azithromycin (AZ) and, group receiving only symptomatic treatment. The study’s primary ' 'objective was to see Clinical response of well-being (CRWB) reporting time after initiating ' 'treatment onset between the four different treatment ' 'arms.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>CRWB did not ' 'differ between the four groups receiving four different managements (p-value 0.846). There ' 'was significant correlation between blood levels of LDH (p-value 0.001), CRP (p-value 0.03) ' 'and D-dimer (p-value 0.04) with CRWB in IVR+DOX group and, between LDH (p-value 0.001), CRP ' '(p-value 0.01) and age (p-value 0.035) with CRWB in the symptomatic management ' 'group.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Mild COVID-19 ' 'infection in patients having low-risk to progress can be managed symptomatically without any ' 'specific drug intervention.</jats:p></jats:sec>', 'DOI': '10.1101/2021.03.08.21252883', 'type': 'posted-content', 'created': {'date-parts': [[2021, 3, 12]], 'date-time': '2021-03-12T14:40:23Z', 'timestamp': 1615560023000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic ' 'of West Bengal: A Retrospective study', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6185-9375', 'authenticated-orcid': False, 'given': 'Sayak', 'family': 'Roy', 'sequence': 'first', 'affiliation': []}, {'given': 'Shambo Samrat', 'family': 'Samajdar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Santanu K', 'family': 'Tripathi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-9524-1525', 'authenticated-orcid': False, 'given': 'Shatavisa', 'family': 'Mukherjee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kingshuk', 'family': 'Bhattacharjee', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021032410001188000_2021.03.08.21252883v2.1', 'unstructured': 'Who.int. Accessed January 16, 2021. https://covid19.who.int/.'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.2', 'unstructured': 'Executive Summary. Therapeutic management of patients with COVID-19. ' 'Nih.gov. Accessed January 16, 2021. ' 'https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_100.pdf'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.3', 'unstructured': 'Gov.in. Accessed January 16, 2021. ' 'https://www.wbhealth.gov.in/uploaded_files/corona/WB_Covid_protocol_book_25.09_.20_(1)_.pdf'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.4', 'unstructured': 'HealthWorld ET. COVID-19: Health Ministry issues revised home isolation ' 'guidelines. PTI. Published July 3, 2020. Accessed January 16, 2021. ' 'https://health.economictimes.indiatimes.com/news/policy/covid-19-health-ministry-issues-revised-home-isolation-guidelines/76767874'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.5', 'unstructured': 'Clinical management of COVID-19. Who.int. Accessed January 16, 2021. ' 'https://www.who.int/publications/i/item/clinical-management-of-covid-19'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.6', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/gutjnl-2020-321852'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.7', 'first-page': '214', 'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'volume': '103', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'issue': '1', 'key': '2021032410001188000_2021.03.08.21252883v2.8', 'doi-asserted-by': 'crossref', 'first-page': '130', 'DOI': '10.1164/rccm.202004-0937LE', 'article-title': 'Outpatient inhaled nitric oxide in a patient with vasoreactive ' 'idiopathic pulmonary arterial hypertension and COVID-19 infection', 'volume': '202', 'year': '2020', 'journal-title': 'Am J Respir Crit Care Med'}, { 'issue': '5', 'key': '2021032410001188000_2021.03.08.21252883v2.9', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of ' 'potential drugs by computational methods', 'volume': '10', 'year': '2020', 'journal-title': 'Acta Pharm Sin B'}, { 'issue': '8', 'key': '2021032410001188000_2021.03.08.21252883v2.10', 'first-page': '1', 'article-title': 'MainakMukhopadhyay. Ventricular arrhythmia risk based on ethnicity in ' 'COVID-19 patients on hydroxychloroquine and azithromycin combination: ' 'Viewpoint', 'volume': '2', 'year': '2020', 'journal-title': 'SN Compr Clin Med'}, { 'issue': '10256', 'key': '2021032410001188000_2021.03.08.21252883v2.11', 'doi-asserted-by': 'crossref', 'first-page': '936', 'DOI': '10.1016/S0140-6736(20)31863-8', 'article-title': 'Azithromycin for severe COVID-19', 'volume': '396', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41421-020-0156-0'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.13', 'unstructured': 'Ncid.sg. Accessed January 16, 2021. ' 'https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Documents/Treatment%20Guidelines%20for%20COVID-19%20%282%20Apr%202020%29%20-final.pdf'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.14', 'unstructured': 'Therapeutic Management. Nih.gov. Accessed January 16, 2021. ' 'https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.15', 'doi-asserted-by': 'crossref', 'unstructured': 'Roy, S. , 2020. Journey So Far With COVID 19 – A Comprehensive Review | ' 'European Journal Of Clinical And Experimental Medicine. [online] ' 'Ejcem.ur.edu.pl. Available at: ' '<http://www.ejcem.ur.edu.pl/summary/journey-so-far-covid-19-comprehensive-review> ' '[accessed 17 January 2021]. ' 'http://www.ejcem.ur.edu.pl/summary/journey-so-far-covid-19-comprehensive-review', 'DOI': '10.15584/ejcem.2020.4.7'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.16', 'unstructured': 'Prophylactic Ivermectin in COVID-19 Contacts. Clinicaltrials.gov. ' 'Accessed January 16, 2021. ' 'https://clinicaltrials.gov/ct2/show/results/NCT04422561.'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.17', 'unstructured': 'USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of ' 'Covid 19 - Study Results - ClinicalTrials.Gov. Clinicaltrials.gov. ' 'Accessed January 16, 2021. ' 'https://clinicaltrials.gov/ct2/show/results/NCT04425850.'}, { 'issue': '2', 'key': '2021032410001188000_2021.03.08.21252883v2.18', 'doi-asserted-by': 'crossref', 'first-page': '106017', 'DOI': '10.1016/j.ijantimicag.2020.106017', 'article-title': 'Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a ' 'report from the Italian front line', 'volume': '56', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.04.061'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-020-05991-x'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.03.08.21252883', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 21]], 'date-time': '2022-12-21T09:03:55Z', 'timestamp': 1671613435000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.03.08.21252883'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 12]]}, 'references-count': 20, 'URL': 'http://dx.doi.org/10.1101/2021.03.08.21252883', 'relation': {}, 'published': {'date-parts': [[2021, 3, 12]]}, 'subtype': 'preprint'}